Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
about
Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New AntibacterialsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciThe mechanism of heterogeneous beta-lactam resistance in MRSA: key role of the stringent stress responseIn vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis PatientCeftaroline fosamil: a brief clinical review.In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011.Investigational antimicrobial agents of 2013.In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolatesActivity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaWhole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyCeftaroline fosamil: a new broad-spectrum cephalosporin.Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Inhibitors targeting on cell wall biosynthesis pathway of MRSA.In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.The hospitalist perspective on treatment of community-acquired bacterial pneumonia.Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus.Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
P2860
Q26749531-18E7569E-16F4-4423-A0BC-E65E454A746CQ26853465-C63F4B51-E21B-4C9A-8236-F2064B1E4C95Q28536588-F327A6B2-C352-4650-A6B7-D1A1995B8272Q33622755-F5085164-A43E-48B9-A185-4E72E2B501A4Q33886807-DD17B2C9-D619-4146-A279-8EFE8427E746Q33939080-EA57A55E-0091-482D-A129-9CFBA6845636Q34363461-6997AB28-D359-4E04-9ACC-CA14264ABE45Q34375204-78F8F960-CEF4-4DFD-99E6-9C693887ACE6Q35004919-24E429CC-884F-429A-8F54-F0DB490FB58BQ35117981-F0C5B9AB-44B4-43AE-AC2A-C7A8014C34F6Q35169054-BF83A335-B734-4ADA-99EF-944114BE90AAQ35191501-E691FBD4-039D-4528-967C-C46C47969EF2Q35191527-7FCF58CB-7E67-4168-A938-4BDB8EB74C03Q35408518-EF759648-60AC-4B99-89B7-DEA4B464E420Q35752997-BB0FEA0D-4251-4C9E-8297-BD8C13FAEFCEQ35927293-86CE4CBB-DD4C-484E-89F6-7C06B22D6F31Q36018756-26169A17-AC75-4500-BDD4-A282E888BA31Q36075871-0123AE96-84B4-4830-B80C-EB5FD46BEC1DQ36363239-3C689B21-5E3D-413E-BDD9-51DC95DB3CBEQ36396172-7F53F8A7-CED6-47DB-8132-E80525790CAEQ36505456-F9E05AF3-AB72-43CD-9E6A-6A2BFA16D14DQ37263425-77161965-FBC5-4A5B-B8CE-71D21DB84D08Q37863942-E35BCC42-2887-4F0C-963F-3AD29F336556Q37947221-AE2848B3-2EA5-497F-B984-C78C1F28CD20Q38006689-F3BFCFA8-51D2-4206-BE0E-18A552C84E4EQ38010783-1BF4AAEA-F547-4C50-9D96-7204A4943A15Q38025132-93F46F02-3A4B-43AE-8977-1C28376E292BQ38035171-BA93D6FC-6718-4BC3-B065-0AC0DE3A4A84Q38035808-9994B61F-3F93-4377-8BD9-7C5D19672C59Q38061168-DC83C9BB-EBA9-4143-8302-DB685A5F8184Q38117077-B2263135-1AF0-4102-96BA-97432D92F551Q38137920-FB428CAA-41F6-494F-8810-7B0FFCE3BA39Q38185097-62E3802C-8BAA-450E-88D7-D8472CE5F88CQ38200827-BAD73CBF-0851-4F9E-84CA-0002889C5A6EQ38232037-6B5182E6-1BF9-4FB6-BC91-B2ECFEA23308Q38262950-5E1DF919-08A5-4113-888A-200FC85CB699Q38270642-B12228C8-C348-4BF9-8E1C-F091C8EF059DQ38394008-34DBA963-AF08-45F5-993D-C05DB2E895F0Q38458802-A32B64E8-696B-4B84-BA48-AFCD3EF47A5EQ38987098-6F9B4580-3B59-428A-A26F-EAE956FE5B6B
P2860
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Affinity of ceftaroline and ot ...... and Streptococcus pneumoniae.
@en
type
label
Affinity of ceftaroline and ot ...... and Streptococcus pneumoniae.
@en
prefLabel
Affinity of ceftaroline and ot ...... and Streptococcus pneumoniae.
@en
P2093
P2860
P356
P1476
Affinity of ceftaroline and ot ...... and Streptococcus pneumoniae.
@en
P2093
K Kosowska-Shick
P C Appelbaum
P L McGhee
P2860
P304
P356
10.1128/AAC.00019-10
P407
P577
2010-03-01T00:00:00Z